Report of β-lactam antibiotic–induced vancomycin-resistant Staphylococcus aureus from a university hospital in Egypt. (May 2019)

• Record Type: Journal Article
• Authors: Taha, A.E.; Badr, M.F.; El-Morsy, F.E.; Hammad, E.
• Is Part Of: New microbes and new infections. Volume 29(2019)
• Publication Date: 2019-05
• Subjects: BIVR -- MRSA -- Staphylococcus aureus -- Vancomycin resistance -- β-lactams; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; Microbiology -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1016/j.nmni.2019.01.003
• Languages: English
• ISSNs: 2052-2975

Abstract

Abstract: We report a case of hospital-acquired pneumonia that to our knowledge is the first description in Egypt of the emergence of vancomycin (VA)-resistant Staphylococcus aureus due to the concomitant use of β-lactams. The combination of β-lactam antibiotics and VA in the treatment of methicillin-resistant S. aureus must be avoided to refrain from inducing VA resistance; further, if there is coinfection with Gram-negative bacilli, β-lactams must be avoided. If β-lactam antibiotic–induced VA-resistant methicillin-resistant S. aureus is isolated, then β-lactams must be avoided until the organism's sensitivity to VA is restored if VA is the only therapeutic option available.